- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 8,371
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer
- Interventions
- Kidney Function Test
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Interventions
- Fludarabine, Melphalan, Antithymocyte Globulin, Sirolimus, Tacrolimus
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 101
- States / cities
- Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- T-DM1, Lapatinib, Abraxane
- Drug
- Lead sponsor
- Jenny C. Chang, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Melanoma
- Interventions
- BMS-986253, Nivolumab, Ipilimumab, Placebo
- Drug · Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 29
- States / cities
- Springdale, Arkansas • Los Angeles, California • Lakewood, Colorado + 24 more
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Sitravatinib, Nivolumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, bevacizumab and bortezomib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bevacizumab, erlotinib hydrochloride, everolimus
- Biological · Drug
- Lead sponsor
- Herbert Hurwitz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
- Interventions
- Ultrasound or abbreviated MRI
- Diagnostic Test
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Tahlequah, Oklahoma
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cancer
- Interventions
- Nivolumab, Subcutaneous nivolumab combined with hyaluronidase
- Drug · Combination Product
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- Pertuzumab, Trastuzumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Duarte, California • Stanford, California + 13 more
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Paclitaxel, Carboplatin, Avastin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 14
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
- Conditions
- Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
- Interventions
- Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more
- Conditions
- Hyperphosphatemia, ESRD
- Interventions
- PKM Algorithm
- Other
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- Hydroxychloroquine, Nelfinavir, Bevacizumab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Lymphoma
- Interventions
- denileukin diftitox, rituximab
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 165
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 104 more
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Disease
- Interventions
- Relatlimab, Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Up to 30 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more
- Conditions
- Locally Advanced or Metastatic Melanoma
- Interventions
- CBL0137, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Bevacizumab, Temsirolimus, Interferon-Alfa 9MU
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Chula Vista, California • La Mesa, California + 11 more
- Conditions
- Bariatric Surgery Candidate, Contraception
- Interventions
- ethinyl estradiol-levonorgestrel
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Depression
- Interventions
- Infliximab, Placebo
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia